人 RUFY3 抗体对
01AB02280
RUN and FYVE domain containing 3 (RUFY3) is a cytosolic adaptor protein that functions as an effector for small GTPases, including Rap2 and ARL8b. In neurons, RUFY3 localizes to growth cones and lipid rafts, where it is essential for establishing neuronal polarity and axon specification by organizing Rap2-dependent actin dynamics. It also acts on endolysosomes by recruiting the JIP4-dynein-dynactin complex to facilitate retrograde lysosome transport and perinuclear positioning. These roles allow RUFY3 to regulate both structural development and organelle distribution. Clinically, RUFY3 overexpression is linked to the progression of gastric cancer. It promotes tumor cell migration and invasion through PAK1-dependent pathways, suggesting a pro-metastatic role in various malignancies.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- RUFY3
- 基因别名
- KIAA0871
- 蛋白别名
- RUN and FYVE domain containing 3; RUFY3
- UniProt
- Q7L099
- 物种
- Human
产品详情
- 靶点名称
- RUFY3
- 蛋白名称
- RUN and FYVE domain containing 3
- 蛋白别名
- Protein RUFY3; RUN and FYVE domain-containing protein 3; Rap2-interacting protein x; RIPx; Single axon-regulated protein; Singar
- 靶点基因名
- RUFY3
- 基因别名
- KIAA0871
- UniProt
- Q7L099
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
RUN and FYVE domain containing 3 (RUFY3) is a cytosolic adaptor protein that functions as an effector for small GTPases, including Rap2 and ARL8b. In neurons, RUFY3 localizes to growth cones and lipid rafts, where it is essential for establishing neuronal polarity and axon specification by organizing Rap2-dependent actin dynamics. It also acts on endolysosomes by recruiting the JIP4-dynein-dynactin complex to facilitate retrograde lysosome transport and perinuclear positioning. These roles allow RUFY3 to regulate both structural development and organelle distribution. Clinically, RUFY3 overexpression is linked to the progression of gastric cancer. It promotes tumor cell migration and invasion through PAK1-dependent pathways, suggesting a pro-metastatic role in various malignancies.